Eisai, Teva end collaboration agreement for rasagiline

By E. Janene Geiss

Philadelphia, July 12 - Eisai Co., Ltd. and Eisai Inc. said Wednesday that they have mutually agreed with Teva Pharmaceutical Industries Ltd. to end a collaboration agreement for rasagiline that was established in May 2003.

Rasagiline was in development to treat Alzheimer's disease. No other details about the drug's development were disclosed.

Eisai Co., Ltd. is a Tokyo-based pharmaceutical company and parent company to Eisai, Inc., which is based in Teaneck, N.J.

Teva is a Petach Tikva, Israel, pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.